Halozyme's pancreatic cancer drug succeeds in mid-stage trial

[January 05, 2017]  (Reuters) - Halozyme Therapeutics Inc said its lead drug to treat a late form of pancreated cancer met the main goal in a mid-stage study, sending its shares soaring in premarket trading.

The study population showed a statistically significant increase in progression-free survival, the company said.

Pancreatic cancer is the third-leading cause of cancer-related death in the United States. [Pn2RDmZDa]

Halozyme's shares were up 44 percent at $15.40 in trading before the opening bell on Thursday.

(Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Ted Kerr)

[© 2017 Thomson Reuters. All rights reserved.]

Copyright 2017 Reuters. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.